Literature DB >> 6304726

Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity.

E P Reddy, M J Smith, A Srinivasan.   

Abstract

The nucleotide sequence of the proviral genome of Abelson murine leukemia virus (A-MuLV), an acute transforming virus of murine origin, has been determined. Like other transforming viruses, A-MuLV contains sequences derived from its helper virus, Moloney murine leukemia virus (M-MuLV), and a cell-derived protooncogene (abl) insertion sequence. By comparison of the A-MuLV sequence with that of M-MuLV, it was possible to precisely localize and define sequences contributed by the host cellular DNA. From the nucleotide sequence, we have predicted the amino acid sequence of p120gag-abl, the product of the A-MuLV gag-abl hybrid gene. The amino acid sequence of the putative abl gene, when compared with the sequences of other tyrosine-specific protein kinases (src, fes, fps, and yes), revealed significant homologies, indicating that all these functionally related transforming genes are derived from divergent members of the same protooncogene family. In addition to the gag-abl sequence, the proviral genome was found to contain an additional open reading frame that could code for an 18,000-dalton protein, whose role is at present undetermined.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6304726      PMCID: PMC394102          DOI: 10.1073/pnas.80.12.3623

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Structure of the Abelson murine leukemia virus genome.

Authors:  A Shields; S Goff; M Paskind; G Otto; D Baltimore
Journal:  Cell       Date:  1979-12       Impact factor: 41.582

2.  Synthesis, surface deposition, and secretion of immunoglobulins by Abelson virus-transformed lymphosarcoma cell lines.

Authors:  E Premkumar; M Potter; P A Singer; M D Sklar
Journal:  Cell       Date:  1975-10       Impact factor: 41.582

3.  Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells.

Authors:  O N Witte; N Rosenberg; M Paskind; A Shields; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

4.  A normal cell protein cross-reactive to the major Abelson murine leukaemia virus gene product.

Authors:  O N Witte; N E Rosenberg; D Baltimore
Journal:  Nature       Date:  1979-10-04       Impact factor: 49.962

5.  Rapid viral induction of plasmacytomas in pristane-primed BALB-c mice.

Authors:  M Potter; M D Sklar; W P Rowe
Journal:  Science       Date:  1973-11-09       Impact factor: 47.728

6.  Influence of prednisolone on Moloney leukemogenic virus in BALB-c mice.

Authors:  H T Abelson; L S Rabstein
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

7.  Biosynthesis of Rauscher leukemia viral proteins.

Authors:  R B Naso; L J Arcement; R B Arlinghaus
Journal:  Cell       Date:  1975-01       Impact factor: 41.582

8.  Terminal transferase-catalyzed addition of nucleotides to the 3' termini of DNA.

Authors:  R Roychoudhury; R Wu
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

9.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

10.  Abelson murine leukemia virus mutants with alterations in the virus-specific P120 molecule.

Authors:  N Rosenberg; O N Witte
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

View more
  106 in total

1.  The common src homology region 2 domain of cytoplasmic signaling proteins is a positive effector of v-fps tyrosine kinase function.

Authors:  C A Koch; M Moran; I Sadowski; T Pawson
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

2.  Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.

Authors:  R W Rees-Jones; S P Goff
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

Review 3.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity.

Authors:  B J Mayer; P K Jackson; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

5.  Phosphorylation of protein 4.1 on tyrosine-418 modulates its function in vitro.

Authors:  G Subrahmanyam; P J Bertics; R A Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

6.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

7.  Delineation of functional determinants in the transforming protein of Fujinami sarcoma virus.

Authors:  K A Johnson; J C Stone
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

8.  Amino acid alterations within a highly conserved region of the Rous sarcoma virus src gene product pp60src inactivate tyrosine protein kinase activity.

Authors:  D L Bryant; J T Parsons
Journal:  Mol Cell Biol       Date:  1984-05       Impact factor: 4.272

9.  Molecular cloning and characterization of avian sarcoma virus UR2 and comparison of its transforming sequence with those of other avian sarcoma viruses.

Authors:  W S Neckameyer; L H Wang
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

10.  Hematopoietic cell transformation by a murine recombinant retrovirus containing the src gene of Rous sarcoma virus.

Authors:  J H Pierce; S A Aaronson; S M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.